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A B S T R A C T
Background
Recent studies have indicated an increased risk of venous thrombosis after air travel.
Nevertheless, questions on the magnitude of risk, the underlying mechanism, and modifying
factors remain unanswered.
Methods and Findings
We studied the effect of various modes and duration of travel on the risk of venous
thrombosis in a large ongoing case-control study on risk factors for venous thrombosis in an
unselected population (MEGA study). We also assessed the combined effect of travel and
prothrombotic mutations, body mass index, height, and oral contraceptive use.
Since March 1999, consecutive patients younger than 70 y with a first venous thrombosis
have been invited to participate in the study, with their partners serving as matched control
individuals. Information has been collected on acquired and genetic risk factors for venous
thrombosis. Of 1,906 patients, 233 had traveled for more than 4 h in the 8 wk preceding the
event. Traveling in general was found to increase the risk of venous thrombosis 2-fold (odds
ratio [OR] 2.1; 95% confidence interval [CI] 1.5–3.0). The risk of flying was similar to the risks of
traveling by car, bus, or train. The risk was highest in the first week after traveling. Travel by car,
bus, or train led to a high relative risk of thrombosis in individuals with factor V Leiden (OR 8.1;
95% CI 2.7–24.7), in those who had a body mass index of more than 30 kg/m2 (OR 9.9; 95% CI
3.6–27.6), in those who were more than 1.90 m tall (OR 4.7; 95% CI 1.4–15.4), and in those who
used oral contraceptives (estimated OR . 20). For air travel these synergistic findings were
more apparent, while people shorter than 1.60 m had an increased risk of thrombosis after air
travel (OR 4.9; 95% CI 0.9–25.6) as well.
Conclusions
The risk of venous thrombosis after travel is moderately increased for all modes of travel.
Subgroups exist in which the risk is highly increased.
The Editors’ Summary of this article follows the references.
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Introduction
Interest in the role of air travel in the pathogenesis of
venous thrombosis has heightened in the past 5 y [1–5].
Venous thrombosis was first linked to air travel in 1954 [6],
and as air travel has become more and more common, many
case reports and case series have been published since.
Several clinical studies have shown an association between air
travel and the risk of venous thrombosis. In a series of
individuals who died suddenly at Heathrow Airport, death
occurred far more often in the arrival than in the departure
area [7]. Two similar studies described a ‘‘dose-response’’
relation: the risk of pulmonary embolism in air travelers
increased with the distance traveled [5,8]. A number of case-
control studies, however, have shown conflicting results [9–
11]. More recently, a 2-fold increased risk in patients who had
traveled by air was described in a case-control study among
210 patients and 210 controls [3]. A case-crossover study
based on record linking in Australia described a 4-fold
increased risk of venous thrombosis in the first 2 wk after a
long-haul flight [1]. In terms of absolute risk, two studies
found similar results: one performed in New Zealand found a
frequency of 1% of venous thrombosis in 878 individuals who
had traveled by air for at least 10 h [2], and a German study
found venous thrombotic events in 2.8% of 964 individuals
who had traveled for more than 8 h in an airplane, as
compared to 1% in 1,213 controls [4]. The events in both
studies were mostly asymptomatic.
The available evidence suggests that the overall risk of
venous thrombosis is moderately increased after air travel.
Nevertheless, many questions remain unanswered: the exact
underlying mechanism is still unknown, and, related to this, it
is not clear whether the risk is increased after air travel only
or after long-distance travel in general. Furthermore, the
effect of the combination of other risk factors for venous
thrombosis and travel has not yet been systematically studied,
with the exception of a study by Martinelli et al., who found
an additionally increased risk in patients with thrombophilia
and patients who used oral contraceptives [3].
The Multiple Environmental and Genetic Assessment
(MEGA) study of risk factors for venous thrombosis is a large
ongoing case-control study aimed at assessing the combined
effect of genetic and acquired risk factors for venous
thrombosis. Cases and control individuals are questioned
about—among many other items—travel that occurred
shortly before the event. This provides an opportunity to
assess the effect of travel on the risk of thrombosis in an
unselected population, as well as the effect of the combina-
tion of travel with several other risk factors for thrombosis.
Methods
Study Design
Since March 1999, consecutive patients younger than 70 y
with a first deep-vein thrombosis (DVT) or pulmonary
embolism (PE) have been identified at six regional anti-
coagulation clinics in the Netherlands. Anticoagulant clinics
monitor the anticoagulant therapy of all patients in a well-
defined geographical area, allowing us to identify consecutive
and unselected patients with thrombosis. Patients who were
unable to fill in the questionnaire (because of language or
severe psychiatric problems), as well as those who died soon
after the venous thrombosis or who were in the end stage of a
disease and for that reason did not participate, were not
included. All others were considered eligible. Partners of
these patients were invited as control individuals, and the
same exclusion criteria were applied.
All participants filled in a detailed standardized question-
naire on general demographic and anthropomorphic char-
acteristics, as well as risk factors for venous thrombosis. The
questionnaire was sent to all participants within a few weeks
after the event and covered the period of 1 y prior to the date
of the thrombotic event (index date). When the participant
was unable to fill in the questionnaire we asked questions by
phone, using a standardized mini-questionnaire. Three
months after the patients had discontinued their oral
anticoagulant therapy, they were invited with their partners
to the anticoagulation clinic for a blood sample. In those
patients who continued to take oral anticoagulant therapy for
more than 1 y after the event, blood was drawn during
therapy. If participants were unable to come to the clinic, a
buccal swab was sent by mail to replace the blood sample for
DNA extraction.
The study protocol was approved by the Ethics Committee
of the Leiden University Medical Center. Written informed
consent was obtained from all participants [12].
Validation Study of Thrombosis Diagnosis
Discharge letters or diagnostic reports of the venous
thrombotic event were obtained for a sample of 742 patients
who had their first thrombosis between March 1999 and
March 2000. The diagnostic management of the patients was
compared to the diagnostic procedure as described in the
Dutch consensus [13]. Diagnosis of clinically suspected DVT
of the leg is based on a clinical score, serial compression
ultrasonography, and D-dimer assay. Objective testing of
clinically suspected pulmonary embolism is based on perfu-
sion and ventilation scintigraphy, ultrasonography of the leg
veins, pulmonary angiography, or helical computed tomo-
graphy. Out of 395 patients with DVT of the leg, 384 (97%)
were objectively diagnosed, while out of 347 patients with PE,
271 (78%) were confirmed with objective testing as certainly
having PE. Since the diagnosis appears to be made by
objective methods in virtually all cases of DVT, while being
more ambiguous for PE, we also analyzed these two
manifestations of venous thrombosis separately.
Current Analysis
For the current analysis we were interested in the effects of
travel, and its combined effect with other common risk
factors for venous thrombosis. Patients with a solitary arm
thrombosis were excluded from this analysis. Of 3,902 eligible
cases, diagnosed up to May 2002, 656 did not participate for
various reasons (such as not willing or not reachable), leading
to a response of 83%. A further 3% responded only to the
mini-questionnaire, taken by phone, which did not contain
questions about travel. Of the remaining 3,111 cases, 78% had
a partner, 77% of whom were willing to participate, which
left 1,867 couples. Additionally, 229 partners were identified
for whom the corresponding patient originally participated
but was later found not to be eligible (aged over 70 y, or not a
first thrombotic event). These control individuals were
matched on sex and 5-y age groups to one of the 557 patients
whose partner did not want to participate, so an extra 229
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pairs were included, making a total of 4,192 participants
(2,096 pairs). As part of the general questionnaire, questions
had been asked about whether or not respondents had
traveled for more than 4 h in the 3 mo before the index date,
about the travel date, and about mode and duration of travel.
We assessed the occurrence of thrombosis in relation to the
period of time that had passed since traveling. Travel was
defined in the analysis as at least one journey with a duration
of at least four uninterrupted hours during the 8-wk period
before the event. During the analysis it appeared that some
individuals had provided dates of travel after the event instead
of before. As there was only one opportunity to fill in such a
date, we had no information about the period before the
event. This was the case in 88 cases and 146 controls. We
excluded these individuals and their partners, which left
3,812 participants (1,906 pairs) for the analysis.
Because we selected the partners of the cases as control
individuals, and because it turned out, as expected, that
couples tend to travel together, we performed a conditional
logistic regression analysis to calculate odds ratios (ORs) for
the relation between travel and venous thrombosis. This
method fully takes this matching into account, and leads to
unbiased estimates, with adjustment for all factors in which
cases and controls tend to be similar, e.g., socioeconomic class
[14]. Details of this method can be found in Protocol S1. The
95% confidence intervals (CIs) were derived from the model.
We assessed the combined effect of traveling and the
following risk factors for thrombosis: factor V Leiden
mutation, prothrombin G20210A mutation, body mass index
(BMI, as kg/m2), and height. We were also interested in the
combined effect of oral contraceptive use and travel.
However, as the control individuals were nearly always of
the opposite sex (partners of the cases were recruited as
controls), it was not possible to perform a matched analysis
for the combination of oral contraceptive use and travel.
Therefore, we performed a case-only analysis [15]. This
method allows one to examine the association between two
exposures among case individuals only. ORs are interpreted
as a synergy index (SI) on a multiplicative scale, with
independence assumed between the exposures. As this
analysis depends only on cases, it was possible to perform it
in all consecutive cases, therefore also including those
without a partner.
Laboratory Measurements
Blood was collected from the antecubital vein into vacuum
tubes containing 0.106 mol/l trisodium citrate. High molec-
ular weight DNA was isolated from leukocytes using a
standard salting-out procedure [16] and stored at 20 8C.
When a blood sample was not available, DNA was extracted
from buccal swabs. Three large cotton swabs in a total of 6 ml
of SDS–proteinase K solution (100 mM NaCl, 10 mM EDTA,
10 mM Tris-HCl [pH 8.0], 0.5% SDS, 0.1 mg/ml proteinase K)
were obtained. Upon arrival, the proteinase K concentration
was raised to 0.2 mg/ml, and the sample was incubated for 2 h
at 65 8C. Subsequently, the solute was recovered by
centrifugation. Potassium acetate was added to the super-
natant to a final concentration of 1.6 M. After 15 min
incubation on ice, proteins were removed using chloroform/
isomylalcohol (24:1) treatment. The DNA in the water phase
was subsequently ethanol precipitated. After centrifugation,
the pellet was resuspended in 200 ll of 10 mM Tris-HCl and
10 mM EDTA (pH 8.0), and frozen at 20 8C until further
analysis. The factor V Leiden mutation (G1691A) and the
prothrombin mutation (G20210A) were simultaneously de-
tected by duplex polymerase chain reaction [17,18]. The
technician was blinded concerning the origin of the sample,
i.e., whether it was from a patient or from a control
individual.
Results
Venous Thrombosis in Relation to Travel
Table 1 shows general characteristics of the 1,906 patients.
They ranged in age from 18 to 69 y (median 50.4 y); 51% were
men. Diagnosis was DVT in 57% of the cases, PE in 32%, and
both in 11%. As partners of the cases were included as
control individuals, the sex distribution of the control
individuals was the opposite; the age distribution differed
only trivially.
Of the patients, 233 individuals (12%) had traveled for at
least 4 h by air, bus, car, or train within the 8 wk preceding
the index date, as compared to 182 of the control individuals
(9.5%). As the cases and control individuals were selected as
couples, many pairs (135) had traveled together and were
uninformative: as a consequence, 145 pairs in which either
the patient (98) or the control (47) had traveled could be used
for the matched analysis (Table 2). This analysis showed a 2-
fold increased risk of venous thrombosis for all modes of
travel combined (OR 2.1; 95% CI 1.5–3.0) compared to not
traveling. For air travel alone, 49 individuals (31 cases and 18
controls) had traveled without their partner, and the analysis
yielded an OR of 1.7 (95% CI 1.0–3.1). For the other modes of
travel (car, bus, and train) the relative risks were essentially
similar to each other and to that of air travel (Table 2).
The risk of venous thrombosis was not clearly related to
increased duration of travel (Table 2). Of the 233 events that
occurred within 8 wk after traveling, 68 (29%) were diagnosed
in the first week, after which the incidence gradually
decreased (Figure 1).
The Effect of Other Risk Factors Combined with Travel
Prothrombotic mutations. Information on the factor V
Leiden mutation and prothrombin G20210A genotype was
available for 1,713 patients (90%) and for 1,629 of the control
individuals (85%). Factor V Leiden was present in 259 cases
(14%) and 84 control individuals (4%) (OR 3.1; 95% CI 2.4–
4.1).
Table 1. Characteristics of the 1,906 Patients with Venous
Thrombosis
Category Characteristic Patients, Number (Percent)
Age (years) ,30 119 (6)
30–44 528 (28)
45–64 996 (52)
65 263 (14)
Sex Men 965 (51)
Women 938 (49)
Diagnosis DVT 1,082 (57)
PE 611 (32)
Both 213 (11)
DOI: 10.1371/journal.pmed.0030307.t001
PLoS Medicine | www.plosmedicine.org August 2006 | Volume 3 | Issue 8 | e3071260
Travel-Related Venous Thrombosis
The risk of venous thrombosis was 8-fold increased in
people with factor V Leiden who had traveled by bus, car, or
train (modes combined) as compared to noncarriers who did
not travel (OR 8.1; 95% CI 2.7–24.7). For the combined effect
of air travel and factor V Leiden, the risk seemed even slightly
higher (OR 13.6; 95% CI 2.9–64.2).
The prothrombin G20210A mutation was found in 83 cases
(4%) and in 29 control individuals (2%) (OR 2.7; 95% CI 1.7–
4.2). The risk in individuals with this mutation who had
traveled was difficult to interpret because of the small
numbers but appeared not to increase more than additively
(Table 3).
BMI. The effect of BMI was studied by dividing individuals
into three categories with the following BMI values: ,25, 25–
30, and .30 kg/m2 [19]. A BMI of 25–30 kg/m2 was associated
with an increased risk of venous thrombosis (OR 1.4; 95% CI
1.2–1.7), and the risk was slightly higher in patients with a
BMI of 30 kg/m2 or more (OR 1.7; 95% CI 1.4–2.1).
The combined effect of a higher BMI and travel was the
sum of the individual risks (Table 3), with the exception of
people with a BMI of more than 30 kg/m2 who traveled by car,
bus, or train, for whom the risk was 10-fold increased (OR 9.9;
95% CI 3.6–27.6). This increase in risk was not found in
people who traveled by air.
Table 2. ORs for Venous Thrombosis in Relation to Travel
Travel
Characteristic
Subcategory Patients
(n ¼ 1,906),
Number
Controls
(n ¼ 1,906),
Number
Pþ, Ca P, Cþb Matched OR (95% CI)
Travelc  1,673 1,724 1
þ 233 182 98 47 2.1 (1.5–3.0)
Air travel  1,673 1,724 1
þ 86 72 31 18 1.7 (1.0–3.1)
Travel by bus  1,673 1,724 1
þ 23 18 11 5 2.2 (0.8–6.3)
Travel by car  1,673 1,724 1
þ 113 86 49 22 2.2 (1.3–3.7)
Travel by train  1,673 1,724 1
þ 11 5 7 2 3.5 (0.8–16.8)
Duration of travel No travel 1,673 1,724 1
48 h 93 62 36 18 2.0
812 h 68 65 33 18 1.8
.12 h 66 51 25 9 2.8
Only the numbers presented in columns 5 and 6 were used for the matched analysis. ORs were calculated as the ratio of discordant pairs, i.e., (Pþ, C)/(P, Cþ) [14]. Minor differences in
numbers are due to missing data.
aThe number of patients (P) that traveled without their partner (C).
bThe number of control individuals that traveled without their partner.
cTravel indicates journey by train, car, bus, or airplane lasting more than 4 h within the 8 wk before venous thrombosis, or corresponding index date for control individuals.
DOI: 10.1371/journal.pmed.0030307.t002
Figure 1. Frequency of the Occurrence of Events within the First 12 wk after Travel
The time window of analysis concerned the first 8 wk.
DOI: 10.1371/journal.pmed.0030307.g001
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Height. Particularly short or tall people may be subjected
during travel to even more unnatural sitting positions than
individuals with average height. Therefore, we assessed the
effect of extremes of heights in combination with travel on
the risk of venous thrombosis by comparing short (less than
1.60 m) and tall individuals (more than 1.90 m) with people of
average height (1.60–1.90 m). Compared to people of average
height, the risk of venous thrombosis was lower for short
people (OR 0.7; 95% CI 0.5–0.9) and did not differ for very
tall individuals (OR 0.9; 95% CI 0.7–1.1). The risk was found
to be increased in people of more than 1.90 m who traveled
(OR 4.7; 95% CI 1.4–15.4 for travel by car, bus, or train; OR
6.8; 95% CI 0.8–60.6 for air travel) compared to non-traveling
people of average height. Interestingly, the risk of venous
thrombosis was also increased in short people but only after
air travel (OR 4.9; 95% CI 0.9–25.6), not after other modes of
travel (OR 1.0; 95% CI 0.3–2.8, all relative to non-traveling
people of average height).
Oral contraception. To study the association between oral
contraceptive use, travel, and the risk of venous thrombosis,
we performed a case-only analysis in all female patients who
were less than 50 y of age. As we needed only cases, it was also
possible to include women without a partner for this analysis,
which led to a total of 1,025 women aged under 50. Non-users
who did not travel were used as the reference group. The
case-only estimate of the SI for women who traveled by car,
bus, or train was 2.4 (95% CI 1.5–3.7). This indicates that the
OR for the combination of travel and oral contraceptive use
is 2.4 times the product of the separate ORs. As oral
contraceptive use generally increases the risk of venous
thrombosis about 4-fold [20], the combination with travel by
car, bus, or train would lead to an estimated OR of about 20
(4 3 2 3 2.4). A clearly stronger interaction of travel by air
with oral contraceptive use was found: the case-only estimate
of the SI was 4.9 (95% CI 2.1– 11.4), which would result in an
OR of about 40 (43 23 4.9).
Effect of Risk Factors in DVT Patients Only
Of the 1,906 cases, 1,082 were diagnosed with DVT. As the
diagnosis was more unambiguous in these patients (97%
objectively diagnosed as compared to 78% of the PE
patients), we repeated the analysis in these patients only.
In this analysis, the overall effect of travel on the risk of
DVT was equal to the effect on all venous thrombosis (DVT
and PE combined). However, here we found a stronger risk
for travel by air (OR 3.0; 95% CI 1.3–7.1) then for travel by
car, bus, or train (OR 1.9; 95% CI 1.1–3.2) (Table 4). Also, the
analysis of the combination of other risk factors with travel
resulted in more clear-cut effects, despite the smaller number
of cases: the risk of DVT was still clearly synergistically
increased in patients with factor V Leiden who traveled,
whereas the prothrombin G20210A mutation did not further
increase the risk of travel (Table 4). Furthermore, a BMI of
more than 30 kg/m2 in combination with travel yielded high
ORs for DVT both in people who traveled by car, bus, or train
and in those who flew. Being more than 1.90 m tall in
combination with travel resulted in higher ORs for DVT; the
risk for short people was more increased after travel by air
(OR 6.8; 95% CI 1.1–43.5) (Table 4). The effect of oral
contraceptive use in combination with travel by car, bus, or
train on the risk of DVT was studied in 589 women and was
somewhat lower than the effect on the risk of all venous
thrombosis (SI 1.9; 95% CI 0.9–4.2). In those who traveled by
air it was also a bit lower (SI 3.4; 95% CI 1.3–8.8), but still
indicative of a strong synergistic effect.
Discussion
In this population-based case-control study, long-distance
traveling increased the risk of venous thrombosis 2-fold.
Travel by air increased the risk to the same extent as travel by
car, bus, or train. The risk was highest in the first week after
traveling. As venous thrombosis is a disease in which many
Table 3. The Combined Effect of Other Risk Factors and Travel on the Risk of Venous Thrombosis (DVT, PE, and Both; 1,906 Pairs)
Risk Factor Subcategory Travel by Car,
Bus, or Train
OR 95% CI Air Travel OR 95% CI
Factor V Leiden   1  1
 þ 2.2 1.3–3.7 þ 2.0 1.0–3.9
þ  3.1 2.3–4.1  3.0 2.3–4.0
þ þ 8.1 2.7–24.7 þ 13.6 2.9–64.2
Prothrombin 20210A   1  1
 þ 1.9 1.3–3.7 þ 2.2 1.3–3.6
þ  2.6 1.6–4.1  2.7 1.7–4.4
þ þ 3.1 0.3–36.6 þ 7.9 0.9–67.2
BMI (kg/m2) ,25  1  1
þ 1.5 0.8–2.6 þ 2.0 1.0–4.1
2530  1.4 1.2–1.7  1.4 1.2–1.7
þ 3.6 2.1–6.3 þ 2.1 1.0–4.4
.30  1.7 1.4–2.1  1.7 1.3–2.1
þ 9.9 3.6–27.6 þ 2.6 1.0–6.4
Height (m) 1.601.90  1  1
þ 2.3 1.5–3.7 þ 1.5 0.9–2.8
,1.60  0.7 0.5–0.9  0.7 0.5–0.9
þ 1.0 0.3–2.8 þ 4.9 0.9–25.6
.1.90  0.9 0.7–1.1  0.9 0.7–1.2
þ 4.7 1.4–15.4 þ 6.8 0.8–60.6
Travel indicates journey by train, car, bus, or airplane lasting more than 4 h within the 8 wk before venous thrombosis, or corresponding index date for control individuals.
DOI: 10.1371/journal.pmed.0030307.t003
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factors (genetic and acquired) interact [21], we identified
groups with additional risk factors in which the risk was
further increased. This was the case for individuals with
factor V Leiden, obese people (BMI . 30 kg/m2), and short
(only for travel by air) and tall people, as well as for women
using oral contraceptives. Some of these synergistic effects
were more apparent for air travel.
Although the studies that have been published so far have
not yielded entirely consistent results, those that did report
an increased risk of venous thrombosis in air travelers
showed similar risk estimates of a 2- to 3-fold increased risk
(even in one with asymptomatic events only [4]). The
occurrence of venous thrombosis was highest in the first
week after travel, and slowly declined afterwards, a pattern
that was also described in a recent record-linking study from
Australia [1], supporting a causal relation.
As a possible mechanism for an extra risk in travelers who
fly, an effect of hypobaric hypoxia on the coagulation system
was postulated, which has already been studied a number of
times, mainly in hypobaric chambers, with unclear results so
far. Our study showed an increased risk in all types of travel,
which suggests that the increased risk of flying is caused
mainly by immobilization. Additionally, the risk is further
increased in short and tall people, who are likely to
experience more immobilization and venous compression
than other travelers. However, as some of our findings were
more pronounced for air travel, we cannot exclude an
additional effect of hypobaric hypoxia, possibly in risk groups
only. This possibility is supported by a recent study of our
group [22] in which we found that thrombin generation
occurred in some healthy volunteers after flying for 8 h but
happened to a far lesser extent after being immobilized for 8
h in a cinema. The high response in the fliers was associated
with the presence of risk factors for thrombosis, i.e., oral
contraceptive use, the factor V Leiden mutation, and the
combination of the two. This finding indicates an effect of an
additional factor in an airplane, such as hypobaric hypoxia, to
which mainly individuals with risk factors respond.
None of the studies published so far have systematically
studied the effect of traveling in combination with other risk
factors, with the exception of the study by Martinelli et al. [3].
In an analysis of 210 patients, they found a 16-fold increased
risk for patients who traveled by air and had some form of
thrombophilia, as well as a 14-fold increased risk in women
who flew and used oral contraceptives, findings that confirm
both the results of the present study and our finding of
activated coagulation in individuals with risk factors after
flying [22].
The finding that taller and shorter people had an increased
risk of venous thrombosis after traveling should be inter-
preted with some caution, as the numbers were small in these
strata. On the other hand, it is biologically plausible: very tall
people are subjected to even more cramped seating than
average-height individuals, and very short people’s feet may
not touch the floor, which would lead to extra compression of
the popliteal veins. Interestingly, the increased risk for short
people was only found in people who traveled by air. This
may have to do with the fact that seats in cars are generally
lower, and more individually adjustable, than those in
airplanes.
As the diagnosis of DVT is usually more unambiguous than
that of PE [23], as was the case in our study population as well,
we repeated the analysis using only DVT as the outcome of
interest (97% objectively diagnosed). In this analysis, despite
using smaller numbers, most findings were either similar or
appeared more evident, and inconsistencies that were found
when using both DVT and PE as endpoints disappeared.
To our knowledge, this is the first large population-based
case-control study in which the effect of travel on the risk of
venous thrombosis has been studied. Because the control
Table 4. The Combined Effect of Other Risk Factors and Travel on the Risk of DVT Only (1,082 Pairs)
Risk Factor Subcategory Travel by Car,
Bus, or Train
OR 95% CI Air Travel OR 95% CI
Factor V Leiden – – 1 – 1
– þ 1.8 0.9–3.5 þ 4.1 1.5–11.2
þ – 4.3 2.9–6.3 – 4.1 2.8–5.9
þ þ 6.2 1.7–22.3 þ 36.1 3.8–344.1
Prothrombin 20210A – – 1 – 1
– þ 1.9 1.0–3.6 þ 3.2 1.3–8.3
þ – 5.0 2.5–9.8 – 4.5 2.3–8.7
þ þ 3.6 0.4–35.7 þ 3.2 0.2–60.5
BMI (kg/m2) ,25 – 1 – 1
þ 1.2 0.6–2.6 þ 3.8 1.4–10.8
25–30 – 1.8 1.4–2.3 – 2.1 1.6–2.9
þ 3.3 1.7–6.6 þ 3.8 1.4–10.5
.30 – 2.1 1.6–2.9 – 3.8 1.4–10.8
þ 29.1 3.7–229.6 þ 7.1 2.0–24.9
Height (m) 1.60–1.90 – 1 – 1
þ 1.8 1.0–3.2 þ 2.7 1.2–6.5
,1.60 – 0.6 0.4–0.8 – 0.6 0.4–0.8
þ 0.7 0.2–2.6 þ 6.8 1.1–43.5
.1.90 – 0.8 0.6–1.2 – 0.8 0.6–1.2
þ 12.9 1.5–107.0 þ 9.4 0.9–97.1
aTravel indicates journey by train, car, bus, or airplane lasting more than 4 h within the 8 wk before venous thrombosis, or corresponding index date for control individuals.
DOI: 10.1371/journal.pmed.0030307.t004
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individuals were closely matched, being partners of the cases,
and couples tend to travel together, only the cases and
control individuals who had not traveled together could be
used for the analysis. Also because of this design, the effect of
sex and age could not be studied. It has to be noted, however,
that for all other research questions on the effect of genetic
and acquired risk factors on the risk of venous thrombosis,
this design has no limitations and the close matching of cases
and controls renders confounding by, for instance, lifestyle
and socioeconomic class less likely than in previous un-
matched studies (see also Protocol S1). Another advantage of
this approach is the minimization of recall bias, as the cases
and controls would generally fill in the questionnaire
together.
Many questions are still left unanswered that necessitate
more research. First of all, our study results apply only to
people younger than 70 y of age. Furthermore, it is likely that
other characteristics exist that also increase the risk—person-
specific (e.g., other drug use), behavioral (e.g., use of sleeping
pills or alcohol consumption), and flight-specific (e.g., class or
seating)—that need to be identified. These further variables
are part of our ongoing study as part of the World Health
Organization Research Initiative into the Global Hazards of
Travel (WRIGHT study). For those who have an increased
risk, such as oral contraceptive users and individuals with
factor V Leiden, prevention may be warranted. Prevention
may vary from simple measures, such as exercises during the
flight, to measures that carry a risk themselves, such as
anticoagulants. Specific studies are needed to assess the
efficacy of these measures and their risk–benefit ratio.
It can be concluded that the risk of venous thrombosis is 2-
fold increased for all travelers and to the same extent for all
modes of travel. In individuals who use oral contraceptives,
are carriers of the factor V Leiden mutation, or are
particularly tall, short, or obese, this risk is considerably
higher, to such an extent that studies into the efficacy of
prophylactic measures are required.
Supporting Information
Alternative Language Abstract S1. Translation of the Abstract into
Dutch by Author
Found at DOI: 10.1371/journal.pmed.0030269.sd001 (25 KB DOC).
Protocol S1. Methodological Appendix
Found at DOI: 10.1371/journal.pmed.0030307.sd002 (210 KB DOC).
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Editors’ Summary
Background. Recently there has been increasing concern that blood
clots (thromboses) in the leg or lungs occur with greater frequency after
air travel. Several theories have been put forward to explain why this
increase might happen, including the fact that air passengers tend to not
move around much, or possibly that reduced amounts of oxygen in the
blood make the blood more likely to clot. Understanding what causes
such clots is important as it would help us come up with suggestions of
ways to prevent them.
Why Was This Study Done? It is not possible to test in a controlled trial
whether travel causes an increase in blood clots, so the next best way of
studying this problem is to do a case-control study, in which people with
blood clots (cases) are compared with similar people who don’t have a
blood clot (controls—in this case, the partners of the cases), and the
differences in a number of contributing factors are assessed.
What Did the Researchers Do and Find? Since 1999, the MEGA
(Multiple Environmental and Genetic Assessment of Risk Factors for
Venous Thrombosis) study has aimed to identify all people in an area of
the Netherlands who develop a blood clot for the first time, by seeking
out people who receive treatment for blood clots. At the time of this
report, 1,906 people with clots had been found; of these, 233 had
traveled for more than four hours in the eight weeks preceding the
event. Traveling in general was found to increase the risk of clots two-
fold, and the risk was highest in the week after traveling. The risk of
flying was similar to the risk of traveling by car, bus, or train, and was
highest in the first week after traveling. Certain other factors increased
the risk of a blood clot even more, such as having a particular mutation
(known as factor V Leiden) in a gene involved in blood clotting, having a
body mass index of more than 30 kg/m2 (over 30 kg/m2 is defined as
being obese), being more than 1.90 meters tall, and using oral
contraceptives. All these factors made the risk of clots especially after
air travel worse; in addition, people shorter than 1.60 meters also had an
increased risk of thrombosis after air travel. However, it should be borne
in mind that the number of cases in each of these various groups was
quite small, and the overall risk of getting a thrombosis is still low.
What Do These Findings Mean? Since the risks of thrombosis are
increased for all types of long travel, it seems that the main factor
causing the thrombosis is immobility. However, since the risk is even
higher for air travel, the relative lack of oxygen may also play a part. One
interesting aspect of this study is that the researchers used partners as
controls; in order to be sure that doing this did not make the results
invalid, the researchers had to carefully adjust for differences between
the cases and controls, such as the fact that partners were generally of
the opposite sex. In a related Perspective (DOI: 10.1371/journal.pmed.
0030300), Kenneth Rothman discusses the study further.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030307.
 MedlinePlus encyclopedia entries on deep venous thrombosis and
pulmonary embolus
 OMNI, a health information service in the UK run by the Resource
Discovery Network, has links to pages of information on venous
thrombosis
 The Web site for the MEGA study in this paper gives further
background and information
 The Web site of the World Health Organization Research Initiative into
Global Hazards of Travel has information on research into the
connection between air travel and venous thrombosis
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